新华财经南京3月6日电(记者朱程)6日,港股上市公司中国生物制药发布公告称,与南京清普生物科技有限公司就其研发的Ⅱ类新药QP001在中国大陆地区达成独家合作协议。该新药已分别在中美两国申报上市,有望成为国内率先上市的长效镇痛NSAIDs(非甾体抗炎药)注射液。目前,临床常用于术后镇痛的药物多需要一日多次注射,或通过留置导管持续给药。QP001是一种长效、强效的新型NSAIDs注射液,可阻断引发身体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.